Digestive organs: Liver: Combined hepatocellular and cholangiocarcinoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Digestive organs: Liver: Combined hepatocellular and cholangiocarcinoma

Identity

Note Defined as an intrahepatic tumor nodule that contains both hepatocellular carcinoma and cholangiocarcinoma.

Other names Hepatocholangiocellular carcinoma

Classification

Note Tumor staging is separated by TNM classification.

TNM classifications for hepatocellular and cholangiocarcinomas of the liver.

Clinics and Pathology

Disease Combined hepatocellular and cholangiocarcinoma is a more aggressive malignancy with a poorer prognosis than ordinary hepatocellular carcinoma (HCC).

Etiology The reported frequency of combined hepatocellular and cholangiocarcinoma (combined tumors) varies widely; 1.0-6.5% among patients with primary liver cancer. Statistical data indicate that combined tumors occur predominantly in men (reported ratio is ranged from 14:1 to 2:1). The mean age of onset is in the sixth decade. In Asian cases, a high incidence of hepatitis B or C virus infection and frequent association of chronic liver disease/cirrhosis have been reported. Conversely, in Western countries, these features are less common. Combined tumors exhibit an invasive character with frequent venous permeation and tumor microsatellite formation, features that are seen more frequently than in ordinary HCC.

Epidemiology A rare subtype of primary liver cancer.

Clinics The typical clinical symptom is abdominal pain. Complaints of fatigue and weakness are mostly attributable to compromised liver function. Jaundice is found in a much lower percentage of patients than of those with intrahepatic cholangiocarcinoma (CC). Chills and fever appear rarely.
In combined tumors, HCC and CC areas rarely can be identified using imaging techniques such as ultrasonography, helical CT, and dynamic MRI. In many cases, even in tumor biopsy samples, the two components are not included or discriminated. Generally, final diagnosis is entrusted to pathological findings of surgically resected or autopsy samples.

Pathology The histopathological classification reported by Goodman et al. is popular:

type I, in which HCC and CC occur coincidentally and no transitional forms are observed;
type II, in which there are areas of apparent transition between HCC and CC;
type III, in which tumor cells resemble the fibrolamellar subtype of HCC but contain mucin-producing glands.
Other classifications, reported by Allen and Lisa, and by Kojiro et al., are known.

(A and B) Gross feature and schematic illustration of combined hepatocellular and cholangiocarcinoma. HCC: hepatocellular carcinoma, CC: cholangiocarcinoma. (C-E) Border zone between HCC and CC. Moderately differentiated HCC (right) with vague grandular component (left). The grandular tumor cells were positive for CK19 and HCC component was positive for Hep par-1.

Treatment Surgical resection, chemotherapy, radiofrequency ablation, microwave coagulation, ethanol injection, transarterial embolization.

Evolution Intrahepatic recurrence is common. Combined tumors have been reported to be more aggressive than HCC, with widespread metastasis and regional lymph node involvement.

Prognosis The prognosis of combined tumors is poorer than that of HCC because of relatively frequent lymph node metastasis and vascular invasion. Survival rates of patients with combined tumors are generally poorer than those of patients with HCC.

Cytogenetics

Note Loss of heterozygosity (LOH) at 4q, 8p, 13q, 16q, and 17p is seen frequently in combined hepatocellular and cholangiocarcinoma similar to in HCC. LOH at 3p and 14q are reported to be specific in CC and combined hepatocellular-cholangiocarcinoma in contrast to HCC.

Genes involved and Proteins

Gene Name K-RAS

Location 12p12.1

Dna / Rna 4 exons

Protein Proto-oncogene. GTP-GDP binding protein with GTPase activity. The K-ras proto-oncogene is thought to exert control over some of the mechanisms of cell growth and differentiation. This gene is converted to an active oncogene by point mutations concentrated significantly in codons 12, 13, and 61.
Mutations of the K-ras gene have been reported to be common (67-75%) in intrahepatic CC. Conversely, the mutations rarely have been found in HCC. K-ras mutations in combined hepatocellular and cholangiocarcinoma have been analyzed in Japanese cases and it has been reported that the mutations were found rarely, as in the case for HCC. This observation may reflect the background of Japanese patients; specifically, chronic hepatitis C infection and evidence of cirrhosis are found in a relatively high percentage of patients with combined hepatocellular and cholangiocarcinoma.

Gene Name p53

Location 17p13

Dna / Rna 11 exons

Protein Tumor suppressor. Wild-type p53 plays an important role in the regulation of the cell cycle process, cell growth, and apoptosis in the event of DNA damage. The aberrant proteins from the mutated genes disrupt critical growth-regulating mechanisms and may play a crucial role in the carcinogenesis. The reported incidence of p53 mutation is 11-37% in intrahepatic CC and 10-29% in combined hepatocellular and cholangiocarcinoma. In HCC, the frequency of p53 mutations varies among different geographic areas. p53 abnormalities appear not to be correlated with tumoral differentiation.

Bibliography

Combined hepatocellular and cholangiocarcinoma.

Wittekind C, Fischer HP, Ponchon T.

In "WHO classification tumors of the digestive system" Hamilton, SR. and Aaltonen, LA (2000) Eds. The IARC Press. REVIEW.

General roles for surgical and pathological studies on cancer of the biliary tract.

Japanese Society of Biliary Surgery.

In "Classification of biliary tract carcinoma" Japanese Society of Biliary Surgery (1997) Kanehara and Co Eds.

Combined liver cell and bile duct carcinoma.

Allen R, Lisa J.

Am J Pathol 1949; 25: 647-655.

Combined hepatocellular and cholangiocarcinoma. A histologic and immunohistochemical study.

Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L.

Cancer 1985; 55: 124-135.

PMID 2578078

Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of c-Ki-ras proto-oncogene.

Tsuda H, Satarug S, Bhudhisawasdi V, Kihana T, Sugimura T, Hirohashi S.

Mol Carcinog 1992; 6: 266-269.

PMID 1336666

Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features.

Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M.

Hum Pathol 1995; 26: 956-964.

PMID 7545644

Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hepatocellular-cholangiocellular carcinomas.

Imai Y, Oda H, Arai M, Shimizu S, Nakatsuru Y, Inoue T, Ishikawa T.

Jpn J Cancer Res 1996; 87: 1056-1062.

PMID 8957064

A clinicopathological study on combined hepatocellular and cholangiocarcinoma.

Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M.

J Gastroenterol Hepatol 1996; 11: 758-764.

PMID 8872774

Combined hepatocellular-cholangiocarcinoma: a clinicopathological study.

Ng IO, Shek TW, Nicholls J, Ma LT.

J Gastroenterol Hepatol 1998; 13: 34-40.

PMID 9737569

Genetic classification of combined hepatocellular-cholangiocarcinoma.

Fujii H, Zhu XG, Matsumoto T, Inagaki M, Tokusashi Y, Miyokawa N, Fukusato T, Uekusa T, Takagaki T, Kadowaki N, Shirai T.

Hum Pathol 2000; 31: 1011-1017.

PMID 11014564

Combined hepatocellular and cholangiocarcinoma. Demographic, clinical, and prognostic factors.

Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, DeMatteo RP, Blumgart LH, Klimstra D.

Cancer 2002; 94: 2040-2046.

PMID 11932907

Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study.

Lee CC, Wu CY, Chen JT, Chen GH.

Hepatogastroenterology 2002; 49: 1487-1490.

PMID 12397714

Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.

Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, Ojima H, Sakamoto M, Takayama T, Makuuchi M.

Jpn J Clin Oncol 2003; 33: 283-287.

PMID 12913082

Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.

Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanche H, Franco D, Monges G, Belghiti J, Sa Cunha A, Laurent-Puig P, Degott C, Zucman-Rossi J.

J Hepatol 2004; 41: 292-298.

PMID 15288479

Clinicopathologic features and prognosis of combined hepatocellular and cholangiocarcinoma.

Koh KC, Lee H, Choi MS, Lee JH, Paik SW, Yoo BC, Rhee JC, Cho JW, Park CK, Kim HJ.

Am J Surg 2005; 189: 120-125.

PMID 15701504

Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.

Aishima S, Kuroda Y, Asayama Y, Taguchi K, Nishihara Y, Taketomi A, Tsuneyoshi M.

Hum Pathol 2006; 37: 283-291.

PMID 16613323

Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.

Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N.

J Hepatobiliary Pancreat Surg 2006; 13: 537-542.

PMID 17139428

Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI.

Sug Today 2006; 36: 892-897.

PMID 16998683

Hepatic progenitor cells in human liver tumor development.

Libbrecht L.

World J Gastroenterol 2006; 12: 6261-6265.

PMID 17072946

A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.

Wakasa T, Wakasa T, Shutou T Hai S, Kubo S, Hirohashi K, Umeshita K, Monden M.

Hepatogastroenterology 2007; 54: 508-513.

PMID 17523309

Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.

Zuo HQ, Yan LN, Zeng Y, Yang JY, Luo HZ, Liu JW, Zhou LX.

Hapatobiliary Pancreat Dis Int 2007; 6: 161-165.

PMID 17374575

REVIEW articles automatic search in PubMed

Last year publications automatic search in PubMed

Contributor(s)

Written 09-2007 Munechika Enjoji, Shinichi Aishima

Department of Hepatology and Pancreatology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan (ME); Department of Pathology, Hamanomachi Hospital, 3-5-27 Maizuru, Chuo-ku, Fukuoka 810-8539, Japan (SA)

Citation

This paper should be referenced as such :
Enjoji M, Aishima S . Digestive organs: Liver: Combined hepatocellular and cholangiocarcinoma. Atlas Genet Cytogenet Oncol Haematol. September 2007 .
URL : http://AtlasGeneticsOncology.org/Tumors/HepatoCholangioCarcID5331.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Apr 17 14:14:34 2008

Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

For comments and suggestions or contributions, please contact us

j.l.huret@chu-poitiers.fr.

Note	Defined as an intrahepatic tumor nodule that contains both hepatocellular carcinoma and cholangiocarcinoma.
Other names	Hepatocholangiocellular carcinoma

Note	Tumor staging is separated by TNM classification.
	TNM classifications for hepatocellular and cholangiocarcinomas of the liver.

Disease	Combined hepatocellular and cholangiocarcinoma is a more aggressive malignancy with a poorer prognosis than ordinary hepatocellular carcinoma (HCC).
Etiology	The reported frequency of combined hepatocellular and cholangiocarcinoma (combined tumors) varies widely; 1.0-6.5% among patients with primary liver cancer. Statistical data indicate that combined tumors occur predominantly in men (reported ratio is ranged from 14:1 to 2:1). The mean age of onset is in the sixth decade. In Asian cases, a high incidence of hepatitis B or C virus infection and frequent association of chronic liver disease/cirrhosis have been reported. Conversely, in Western countries, these features are less common. Combined tumors exhibit an invasive character with frequent venous permeation and tumor microsatellite formation, features that are seen more frequently than in ordinary HCC.
Epidemiology	A rare subtype of primary liver cancer.
Clinics	The typical clinical symptom is abdominal pain. Complaints of fatigue and weakness are mostly attributable to compromised liver function. Jaundice is found in a much lower percentage of patients than of those with intrahepatic cholangiocarcinoma (CC). Chills and fever appear rarely. In combined tumors, HCC and CC areas rarely can be identified using imaging techniques such as ultrasonography, helical CT, and dynamic MRI. In many cases, even in tumor biopsy samples, the two components are not included or discriminated. Generally, final diagnosis is entrusted to pathological findings of surgically resected or autopsy samples.
Pathology	The histopathological classification reported by Goodman et al. is popular: type I, in which HCC and CC occur coincidentally and no transitional forms are observed; type II, in which there are areas of apparent transition between HCC and CC; type III, in which tumor cells resemble the fibrolamellar subtype of HCC but contain mucin-producing glands. Other classifications, reported by Allen and Lisa, and by Kojiro et al., are known.


	(A and B) Gross feature and schematic illustration of combined hepatocellular and cholangiocarcinoma. HCC: hepatocellular carcinoma, CC: cholangiocarcinoma. (C-E) Border zone between HCC and CC. Moderately differentiated HCC (right) with vague grandular component (left). The grandular tumor cells were positive for CK19 and HCC component was positive for Hep par-1.

Treatment	Surgical resection, chemotherapy, radiofrequency ablation, microwave coagulation, ethanol injection, transarterial embolization.
Evolution	Intrahepatic recurrence is common. Combined tumors have been reported to be more aggressive than HCC, with widespread metastasis and regional lymph node involvement.
Prognosis	The prognosis of combined tumors is poorer than that of HCC because of relatively frequent lymph node metastasis and vascular invasion. Survival rates of patients with combined tumors are generally poorer than those of patients with HCC.

Gene Name	K-RAS
Location	12p12.1
Dna / Rna	4 exons
Protein	Proto-oncogene. GTP-GDP binding protein with GTPase activity. The K-ras proto-oncogene is thought to exert control over some of the mechanisms of cell growth and differentiation. This gene is converted to an active oncogene by point mutations concentrated significantly in codons 12, 13, and 61. Mutations of the K-ras gene have been reported to be common (67-75%) in intrahepatic CC. Conversely, the mutations rarely have been found in HCC. K-ras mutations in combined hepatocellular and cholangiocarcinoma have been analyzed in Japanese cases and it has been reported that the mutations were found rarely, as in the case for HCC. This observation may reflect the background of Japanese patients; specifically, chronic hepatitis C infection and evidence of cirrhosis are found in a relatively high percentage of patients with combined hepatocellular and cholangiocarcinoma.

Gene Name	p53
Location	17p13
Dna / Rna	11 exons
Protein	Tumor suppressor. Wild-type p53 plays an important role in the regulation of the cell cycle process, cell growth, and apoptosis in the event of DNA damage. The aberrant proteins from the mutated genes disrupt critical growth-regulating mechanisms and may play a crucial role in the carcinogenesis. The reported incidence of p53 mutation is 11-37% in intrahepatic CC and 10-29% in combined hepatocellular and cholangiocarcinoma. In HCC, the frequency of p53 mutations varies among different geographic areas. p53 abnormalities appear not to be correlated with tumoral differentiation.

REVIEW articles	automatic search in PubMed
Last year publications	automatic search in PubMed

Written	09-2007	Munechika Enjoji, Shinichi Aishima
		Department of Hepatology and Pancreatology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan (ME); Department of Pathology, Hamanomachi Hospital, 3-5-27 Maizuru, Chuo-ku, Fukuoka 810-8539, Japan (SA)